Abstract

Hereditary Hemochromatosis (HH) is a genetic disorder characterized by abnormal iron metabolism, leading to excessive iron absorption and deposition in various organs. This iron overload can result in severe complications, including liver cirrhosis, diabetes, and cardiomyopathy. Traditional treatment approaches for HH primarily involve therapeutic phlebotomy to reduce iron levels; however, the emergence of iron chelators has expanded therapeutic options. This review explores the role of iron chelators in the management of Hereditary Hemochromatosis. We delve into the mechanisms of iron chelation, discussing how these agents bind and eliminate excess iron, preventing its accumulation in vital organs. Various iron chelators, including deferoxamine, deferiprone, and deferasirox, are scrutinized for their efficacy, safety profiles, and potential side effects. While therapeutic phlebotomy remains a cornerstone in HH management, the integration of iron chelators as adjunctive or alternative therapies presents a promising avenue.